<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Modern Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Modern Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Современная онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1815-1434</issn><issn publication-format="electronic">1815-1442</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">679131</article-id><article-id pub-id-type="doi">10.26442/18151434.2025.1.203198</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Isolated metastatic lesion of hyoid bone in gastric cancer: A rare case</article-title><trans-title-group xml:lang="ru"><trans-title>Изолированное метастатическое поражение подъязычной кости при раке желудка: необычный случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4045-1247</contrib-id><name-alternatives><name xml:lang="en"><surname>Ognerubov</surname><given-names>Nikolai A.</given-names></name><name xml:lang="ru"><surname>Огнерубов</surname><given-names>Николай Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), D. Sci. (Law), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, д-р юрид. наук, проф., проф. каф. онкологии и паллиативной медицины им. А.И. Савицкого, засл. работник высшей школы РФ, засл. врач РФ</p></bio><email>ognerubov_n.a@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4165-8397</contrib-id><name-alternatives><name xml:lang="en"><surname>Antipova</surname><given-names>Tatiana S.</given-names></name><name xml:lang="ru"><surname>Антипова</surname><given-names>Татьяна Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Radiologist</p></bio><bio xml:lang="ru"><p>врач-радиолог</p></bio><email>ognerubov_n.a@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">PET-Technology</institution></aff><aff><institution xml:lang="ru">Федеральная сеть центров ядерной медицины «ПЭТ-технолоджи»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-05-04" publication-format="electronic"><day>04</day><month>05</month><year>2025</year></pub-date><volume>27</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>32</fpage><lpage>35</lpage><history><date date-type="received" iso-8601-date="2025-05-03"><day>03</day><month>05</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-05-03"><day>03</day><month>05</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://modernonco.orscience.ru/1815-1434/article/view/679131">https://modernonco.orscience.ru/1815-1434/article/view/679131</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Secondary hyoid tumors are extremely rare. There are few documented reports of metastases into hyoid in patients with distant localizations of malignancies, such as breast, lung, kidney, liver, and sigmoid colon cancers. The article describes a rare case of metastases of advanced gastric cancer to the hyoid bone.</p> <p><bold>Aim. </bold>To present a clinical case of isolated metastatic lesion of the hyoid bone in a patient with primary advanced gastric cancer, demonstrating the possibility of increasing the duration and quality of life using polychemotherapy.</p> <p><bold>Results.</bold> A 54-year-old male with synchronous pain in the throat and epigastrium when swallowing solid food and weight loss underwent esophagogastroduodenoscopy, which showed a defect in the mucosa along a small curvature in the middle third of the stomach. Histological examination showed colloid cancer. Combined positron-emission and X-ray computed tomography (PET/CT) with <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) revealed a gastric tumor with radiopharmaceutical hyper uptake, serous membrane invasion and involvement of paragastric, celiac, retroperitoneal, and mediastinal lymph nodes. The entire hyoid bone was swollen with fragmentary cortex destruction. Stage IV gastric cancer cT4bN3аM1 was diagnosed with metastases to the hyoid bone, mediastinal, and retroperitoneal lymph nodes. The patient received eight cycles of polychemotherapy with the XELOX regimen and reported the resolution of sore throat and epigastric pain. The results of PET/CT with <sup>18</sup>F-FDG showed sclerosis of the cortical layer of the hyoid bone and no abnormal radiopharmaceutical uptake. The patient has been alive for 13 months.</p> <p><bold>Conclusion.</bold> Hypoglossal bone metastases are extremely rare in patients with advanced colloid cancer. Such case was described for the first time. The method of choice for diagnosing and assessing the extent of the tumor is PET/CT with <sup>18</sup>F-FDG. Palliative polychemotherapy can increase the duration and improve the quality of life.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> В клинической практике вторичные опухоли подъязычной кости встречаются крайне редко. Имеются задокументированные немногочисленные сообщения о метастазах в нее при дистантных локализациях злокачественных новообразований, таких как рак молочной железы, легких, почек, печени и сигмовидной кишки. В статье освещается необычный случай, связанный с метастазами распространенного рака желудка в подъязычную кость.</p> <p><bold>Цель. </bold>Представить клинический случай изолированного метастатического поражения подъязычной кости у больного первичным распространенным раком желудка, демонстрирующий возможность увеличения продолжительности и качества жизни с помощью полихимиотерапии.</p> <p><bold>Результаты. </bold>У 54-летнего мужчины при эзофагогастродуоденоскопии по поводу синхронных болей в горле при глотании твердой пищи и эпигастрии, похудения выявлен дефект слизистой по малой кривизне в средней трети желудка. При гистологическом исследовании установлен перстневидноклеточный рак. По данным комбинированной позитронно-эмиссионной и рентгеновской компьютерной томографии (ПЭТ/КТ) с <sup>18</sup>F-фтордезоксиглюкозой (<sup>18</sup>F-ФДГ) выявлена опухоль желудка с гиперфиксацией радиофармпрепарата, прорастающая серозную оболочку, с поражением парагастральных, чревных, забрюшинных лимфоузлов и лимфоузлов средостения. Подъязычная кость вздута на всем протяжении с фрагментарной деструкцией кортикального отдела. Установлен диагноз рака желудка стадии IV cT4bN3аM1, обнаружены метастазы в подъязычную кость, лимфоузлы средостения и забрюшинные лимфоузлы. Проведено 8 циклов полихимиотерапии по схеме XELOX. Клинически пациент отметил прекращение болей в горле и эпигастрии. Результаты ПЭТ/КТ с <sup>18</sup>F-ФДГ показали склероз кортикального слоя подъязычной кости и отсутствие накопления радиофармпрепарата. Пациент жив на протяжении 13 мес.</p> <p><bold>Заключение.</bold> При распространенном перстневидноклеточном раке желудка крайне редко наблюдаются метастазы в подъязычную кость. Представленный случай описан впервые. Методом постановки диагноза и оценки распространенности опухолевого процесса при этом является ПЭТ/КТ с <sup>18</sup>F-ФДГ. Применение паллиативной полихимиотерапии позволяет увеличить продолжительность и улучшить качество жизни.</p></trans-abstract><kwd-group xml:lang="en"><kwd>gastric cancer</kwd><kwd>advanced</kwd><kwd>colloid cancer</kwd><kwd>hyoid bone</kwd><kwd>metastasis</kwd><kwd>combined positron emission and X-ray computed tomography</kwd><kwd>PET/CT</kwd><kwd>polychemotherapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак желудка</kwd><kwd>распространенный</kwd><kwd>перстневидноклеточный</kwd><kwd>подъязычная кость</kwd><kwd>метастаз</kwd><kwd>комбинированная позитронно-эмиссионная и рентгеновская компьютерная томография</kwd><kwd>ПЭТ/КТ</kwd><kwd>полихимиотерапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Rivera-Serrano CM, Branstetter BF 4th, Johnson JT. Osteoblastoma of the hyoid bone. AJNR Am J Neuroradiol. 2010;31(6):1080-1. DOI:10.3174/ajnr.A1872</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zhang YH, He YF, Yue H, et al. Solitary hyoid plasmacytoma with unicentric Castleman disease: A case report and review of literature. World J Clin Cases. 2022;10(36):13364-72. DOI:10.12998/wjcc.v10.i36.13364</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kusama H, Okishiro M, Ishida T, et al. A case of hyoid bone metastasis from breast cancer. Gan Kagaku Ryoho. 2014;41:1915-7.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Iguchi H, Okabe Y, Takayama M, et al. Solitary hyoid bone metastasis from hepatocellular carcinoma treated with surgery. Nihon Jibiinkoka Gakkai Kaiho. 2012;115(8):783-6. DOI:10.3950/jibiinkoka.115.783</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Passah A, Agarwal KK, ArunRaj ST, et al. A rare site of hyoid bone metastasis in patients with renal cell carcinoma on 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan. Indian J Nucl Med. 2016;31(4):319. DOI:10.4103/0972-3919.190806</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Aljariri AA, Nashwan AJ, Hammoud R, et al. Metastatic sigmoid adenocarcinoma to the larynx: A case report and updated literature review. Clin Case Rep. 2023;11:e6942.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Di Marco GP, Tucci C, Iacomino E, et al. Hyoid Bone Metastases: An Unusual Case. Reports. 2023;6:59. DOI:10.3390/reports6040059</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ryan JF, Xie DX, Eytan DF, et al. Melanoma metastatic to the hyoid bone. Clin Case Rep. 2020;9(1):522-5. DOI:10.1002/ccr3.3571</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lee HS, Lee JH, Kim SW, Lee KD. Metastatic renal cell carcinoma to the hyoid bone. Otolaryngol Head Neck Surg. 2010;142(6):913-4. DOI:10.1016/j.otohns.2010.01.002</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zhang HY, Shan Li S, Guo X, et al. Hyoid Bone Metastasis in Patients With Lung Adenocarcinoma: A Case Report. Ear, Nose Throat J. 2020;014556132091698. DOI:10.1177/0145561320916985</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Bracanovic D, Vukovic V, Janovic A, et al. Hyoid Bone and Thyroid Cartilage Metastases from Sigmoid Colon Adenocarcinoma: A Case Report. Balkan Med J. 2017;34(3):278-80. DOI:10.4274/balkanmedj.2015.1817</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Hsu J, Hribar K, Poen J. Radiotherapy for hyoid bone metastasis from lung adenocarcinoma: A case report. World J Clin Oncol. 2024;15(1):159-64. DOI:10.5306/wjco.v15.i1.159</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Timon CI, Gullane PJ, Brown D, Van Nostrand AW. Hyoid bone involvement by squamous cell carcinoma: clinical and pathological features. Laryngoscope. 1992;102(5):515-20. DOI:10.1288/00005537-199205000-00008</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Fujita I, Toyokawa T, Makino T, et al. Small early gastric cancer with synchronous bone metastasis: A case report. Mol Clin Oncol. 2020;12:202-7. DOI:10.3892/mco.2020.1985</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ameur WB, Belghali S, Akkari I, et al. Bone metastasis as the first sign of gastric cancer. Pan Afr Med J. 2017;28:95. DOI:10.11604/pamj.2017.28.95.13787</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Dassen AE, Lips DJ, Hoekstra CJ, et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol. 2009;35(5):449-55. DOI:10.1016/j.ejso.2008.11.010</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France: International Agency for Research on Cancer. Available at: https://gco.iarc.who.int/today/ Accessed: 02.02.2024.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Yoshikawa K, Kitaoka H. Bone metastasis of gastric cancer. Jpn J Surg. 1983;13:173-6.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Park JM, Song KY, O JH, et al. Bone recurrence after curative resection of gastric cancer. Gastric Cancer. 2013;16(3):362-9. DOI:10.1007/s10120-012-0193-y</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kobayashi M, Okabayashi T, Sano T, Araki K. Metastatic bone cancer as a recurrence of early gastric cancer -- characteristics and possible mechanisms. World J Gastroenterol. 2005;11(36):5587-91. DOI:10.3748/wjg.v11.i36.5587</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kang SH, Kim JI, Moon HS, et al. Overt bone marrow metastasis from early gastric cancer. Endoscopy. 2008;40 Suppl. 2:E34-5. DOI:10.1055/s-2007-966860</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ma DW, Kim JH, Jeon TJ, et al. ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography for the evaluation of bone metastasis in patients with gastric cancer. Dig Liver Dis. 2013;45(9):769-75. DOI:10.1016/j.dld.2013.02.009</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kawanaka Y, Kitajima K, Fukushima K, et al. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT. Eur J Radiol. 2016;85(5):989-95. DOI:10.1016/j.ejrad.2016.03.003</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215-21. DOI:10.1016/S1470-2045(08)70035-4</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Shitara K, Takashima A, Fujitani K, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(4):277-87. DOI:10.1016/S2468-1253(16)30219-9</mixed-citation></ref></ref-list></back></article>
